BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 16392437)

  • 1. [Primary and secondary prevention of cardiovascular events through hormone replacement therapy (HRT)].
    Pilz H
    Wien Med Wochenschr; 2005 Sep; 155(17-18):397-403. PubMed ID: 16392437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The choice of hormone replacement therapy or statin therapy in the treatment of hyperlipidemic postmenopausal women.
    Seed M
    Atheroscler Suppl; 2002 May; 3(1):53-63. PubMed ID: 12044587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relevance of the Women's Health Initiative results on combined hormone replacement therapy in clinical practice.
    Lemay A
    J Obstet Gynaecol Can; 2002 Sep; 24(9):711-5. PubMed ID: 12360366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Heart and Estrogen/Progestin Replacement Study: what have we learned and what questions remain?
    Wells G; Herrington DM
    Drugs Aging; 1999 Dec; 15(6):419-22. PubMed ID: 10641952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormone replacement therapy trials: an update.
    Duvernoy CS; Mosca L
    Curr Atheroscler Rep; 2002 Mar; 4(2):156-60. PubMed ID: 11822980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postmenopausal hormone therapy: cardiovascular risks.
    Prescrire Int; 2003 Apr; 12(64):65-9. PubMed ID: 12674130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postmenopausal hormone replacement therapy: scientific review.
    Nelson HD; Humphrey LL; Nygren P; Teutsch SM; Allan JD
    JAMA; 2002 Aug; 288(7):872-81. PubMed ID: 12186605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).
    Grady D; Herrington D; Bittner V; Blumenthal R; Davidson M; Hlatky M; Hsia J; Hulley S; Herd A; Khan S; Newby LK; Waters D; Vittinghoff E; Wenger N;
    JAMA; 2002 Jul; 288(1):49-57. PubMed ID: 12090862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause.
    Shlipak MG; Simon JA; Vittinghoff E; Lin F; Barrett-Connor E; Knopp RH; Levy RI; Hulley SB
    JAMA; 2000 Apr; 283(14):1845-52. PubMed ID: 10770146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving issues in the clinical and managed care settings on the management of menopause following the women's health initiative.
    Lukes A
    J Manag Care Pharm; 2008 Apr; 14(3 Suppl):7-13. PubMed ID: 18439061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical monograph: hormone replacement therapy.
    Deady J
    J Manag Care Pharm; 2004; 10(1):33-47. PubMed ID: 14720104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipids and cardiovascular disease: do the findings and therapy apply equally to men and women?
    LaRosa JC
    Womens Health Issues; 1992; 2(2):102-11; discussion 111-3. PubMed ID: 1617306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen replacement therapy and the prevention of coronary heart disease in postmenopausal women.
    Contreras I; Parra D
    Am J Health Syst Pharm; 2000 Nov; 57(21):1963-8; quiz 1969-71. PubMed ID: 11094650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics.
    Grady D; Applegate W; Bush T; Furberg C; Riggs B; Hulley SB
    Control Clin Trials; 1998 Aug; 19(4):314-35. PubMed ID: 9683309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Menopause and hormone replacement therapy (HRT) in women with diabetes].
    Cyganek K
    Przegl Lek; 1999; 56(5):362-71. PubMed ID: 10554574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone replacement therapy, selective estrogen receptor modulators, and tissue-specific compounds: cardiovascular effects and clinical implications.
    Vogelvang TE; van der Mooren MJ; Mijatovic V
    Treat Endocrinol; 2004; 3(2):105-15. PubMed ID: 15743106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.
    Anderson GL; Limacher M; Assaf AR; Bassford T; Beresford SA; Black H; Bonds D; Brunner R; Brzyski R; Caan B; Chlebowski R; Curb D; Gass M; Hays J; Heiss G; Hendrix S; Howard BV; Hsia J; Hubbell A; Jackson R; Johnson KC; Judd H; Kotchen JM; Kuller L; LaCroix AZ; Lane D; Langer RD; Lasser N; Lewis CE; Manson J; Margolis K; Ockene J; O'Sullivan MJ; Phillips L; Prentice RL; Ritenbaugh C; Robbins J; Rossouw JE; Sarto G; Stefanick ML; Van Horn L; Wactawski-Wende J; Wallace R; Wassertheil-Smoller S;
    JAMA; 2004 Apr; 291(14):1701-12. PubMed ID: 15082697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone replacement therapy and stroke.
    Billeci AM; Paciaroni M; Caso V; Agnelli G
    Curr Vasc Pharmacol; 2008 Apr; 6(2):112-23. PubMed ID: 18393913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen plus progestin and the risk of coronary heart disease.
    Manson JE; Hsia J; Johnson KC; Rossouw JE; Assaf AR; Lasser NL; Trevisan M; Black HR; Heckbert SR; Detrano R; Strickland OL; Wong ND; Crouse JR; Stein E; Cushman M;
    N Engl J Med; 2003 Aug; 349(6):523-34. PubMed ID: 12904517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time trends in the HERS secondary prevention trial: much ado about nothing?
    Derry PS
    J Am Med Womens Assoc (1972); 2002; 57(4):215-6. PubMed ID: 12405240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.